FY2029 Earnings Forecast for ZNTL Issued By HC Wainwright

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a research report issued on Wednesday, January 29th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.58) per share for the year. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.48) per share.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36.

Several other analysts also recently weighed in on the stock. Guggenheim lowered their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. UBS Group reduced their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research report on Tuesday. Wells Fargo & Company dropped their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday. Finally, Wedbush reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Zentalis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL opened at $1.66 on Friday. Zentalis Pharmaceuticals has a fifty-two week low of $1.66 and a fifty-two week high of $18.07. The firm has a market cap of $118.30 million, a price-to-earnings ratio of -0.67 and a beta of 1.86. The firm has a 50 day moving average price of $2.97 and a 200-day moving average price of $3.29.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ZNTL. Erste Asset Management GmbH purchased a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth approximately $37,000. Paloma Partners Management Co bought a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter worth about $37,000. Aigen Investment Management LP purchased a new position in Zentalis Pharmaceuticals during the 3rd quarter valued at about $41,000. Capstone Investment Advisors LLC bought a new stake in Zentalis Pharmaceuticals during the third quarter worth about $48,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after purchasing an additional 5,333 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.